Abstract: Nanostructured lipid carriers (NLCs) are revolutionary lipid-based drug delivery systems composed of biocompatible solid and liquid lipids combined with surfactants and co-surfactants. Their structural flexibility and favourable safety profile have supported their increasing use in nanotechnology for the delivery of a broad range of therapeutic agents. Newly, the application of artificial intelligence (AI) in NLC-based drug delivery has been revealed as an approach to advance formulation design and aiming competence in colon cancer treatment. Machine learning and predictive modelling methodologies allow organized analysis of formulation variables and assistance in forecasting carrier performance. NLCs, classified as second-generation lipid carriers, are entering the market to overcome the issues of solid lipid nanoparticles (SLNs), such as low drug loading and drug leakage during storage. Although initially investigated primarily for lipophilic drugs, subsequent research has demonstrated their suitability for hydrophilic compounds. Their high biocompatibility and low immunogenicity further support their use in safe drug delivery applications. This review scrutinizes the considerations behind formulation design, various structural features, and manufacturing procedures of NLCs, with prominence on their benefits over earlier lipid-based carriers. In addition, therapeutic applications are précised, and the prospective role of AI-assisted formulation approaches in improving directing accuracy and therapeutic results in colon cancer is discussed.
Rane et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: